摘要
目的分析盐酸曲美他嗪对缺血性心肌病慢性心力衰竭患者心脏重构及左室射血功能的影响。方法将2015年3月至2018年8月本院收治的缺血性心肌病慢性心力衰竭患者80例按照随机分组原则分为对照组和研究组,各40例。对照组采用临床常规治疗,研究组在对照组的基础上采用盐酸曲美他嗪治疗。比较两组临床疗效、治疗前、后心功能、6 min步行距离、CRP、血脂水平及不良反应发生情况。结果研究组的治疗总有效率为95.00%,显著高于对照组的72.50%(P<0.05)。治疗后,两组LVESD、LVEDD较治疗前均降低,LVEF较治疗前均升高,且研究组优于对照组(P<0.05)。治疗后,两组的6 min步行距离均长于治疗前,且研究组长于对照组(P<0.05)。治疗后,两组的CRP水平均降低,且研究组低于对照组(P<0.05)。治疗后,两组的LDL-C、TC、TG水平均降低,HDL-C水平均升高,且研究组优于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论盐酸曲美他嗪可有效改善缺血性心肌病慢性心力衰竭患者的心功能,增强左室射血功能,且不良反应较少,安全性较高,效果显著,值得临床借鉴和进一步推广应用。
Objective To analyze the effect of trimetazidine hydrochloride on cardiac remodeling and left ventricular ejection function in patients with chronic heart failure due to ischemic cardiomyopathy. Methods Eighty patients with chronic heart failure due to ischemic cardiomyopathy admitted in our hospital from March 2015 to August 2018 were divided into control group and study group by random grouping principle, with 40 cases in each group. The control group adopted clinical routine treatment, while the study group was treated with trimetazidine hydrochloride on the basis of the control group. The clinical efficacy, cardiac function, 6-min walking distance, levels of CRP and blood lipid before and after treatment and adverse reactions of the two groups were compared. Results After treatment, the total effective rate of treatment in the study group was 95.00%, which was significantly higher than 72.50% in the control group(P<0.05). After treatment, the LVESD and LVEDD were lower than those before treatment, and the LVEF were higher than those before treatment in the two groups, and those of the study group were better than the control group(P<0.05). After treatment, the6-minute walking distance of the two groups were longer than that before treatment, and that of the study group was longer than the control group(P <0.05). After treatment, the levels CRP of both groups decreased, and that in the study group was lower than the control group(P <0.05). After treatment, the levels of LDL-C, TC and TG in both groups decreased, while the levels of HDL-C increased, and those of the study group were better than the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Trimetazidine hydrochloride can effectively improve cardiac function and enhance left ventricular ejection function in patients with chronic heart failure due to ischemic cardiomyopathy, with fewer adverse reactions, higher safety and significant effect, which is worthy of clinical reference and further promotion and application.
作者
郭亚妮
白成斌
GUO Ya-ni;BAI Cheng-bin(Shenhua Shendong General Hospital, Yulin 719315, China)
出处
《临床医学研究与实践》
2019年第11期25-27,共3页
Clinical Research and Practice
关键词
盐酸曲美他嗪
缺血性心肌病
慢性心力衰竭
心脏重构
左室射血功能
trimetazidine hydrochloride
ischemic cardiomyopathy
chronic heart failure
cardiac remodeling
left ventricular ejection function
